Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
/in International Publications, Newcastle Disease VirusThe role of the immune system in the control of hepatocellular carcinoma
/in Hepatocellular Carcinoma, International PublicationsImmunotherapeutic strategies for hepatocellular carcinoma
/in Hepatocellular Carcinoma, International PublicationsClinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease VirusPhase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: planned interim analysis
/in International Publications, Malignant MelanomaDendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy
/in Gastric Cancer, International PublicationsAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusDendritic cell-based immunotherapy in thyroid malignancies
/in Dendritic Cells, International Publications, Thyroid Cancer[Immunotherapy–perspectives in therapy of ovarian carcinomas]
/in International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer